Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Oncology

MALT, Nodal, and Splenic: The Three Subtypes of MZL

At a Glance

Marginal Zone Lymphoma (MZL) has three main subtypes: MALT, Splenic, and Nodal. Because each subtype starts in different parts of the body and has unique triggers like chronic infections or autoimmune conditions, identifying your specific subtype is the critical first step in determining your treatment plan.

Marginal Zone Lymphoma (MZL) is not just one disease; it is a group of three distinct subtypes that behave differently based on where they start in the body [1][2]. Identifying your specific subtype is the critical first step in your care because it determines whether your treatment will involve antibiotics, targeted immunotherapy, or simple monitoring [3][4].

The Three Faces of MZL

Each subtype is named for the primary location where the lymphoma cells are found.

1. Extranodal MALT Lymphoma (~60-70% of cases)

MALT stands for Mucosa-Associated Lymphoid Tissue. This is the most common form and occurs in tissues outside the lymph nodes—most frequently the stomach (gastric MALT), but also the lungs, salivary glands, skin, and eyes [5][6].

  • The Chronic Trigger: MALT lymphoma is often the result of the body’s immune system overreacting to a long-term infection or an autoimmune condition [7]. For example, most gastric MALT cases are triggered by the H. pylori bacterium [8].
  • Behavior: It tends to stay localized to one area for a long time [3].

2. Splenic MZL (~10% of cases)

As the name suggests, Splenic Marginal Zone Lymphoma (SMZL) begins in the spleen. It often involves the bone marrow and blood as well [9][10].

  • The Chronic Trigger: SMZL has a strong association with the Hepatitis C virus (HCV). In some cases, treating the virus can actually make the lymphoma regress [8PREWZNC].
  • Behavior: Many patients have no symptoms and can be managed with a “watch and wait” approach for years [4].

3. Nodal MZL (~10-30% of cases)

Nodal Marginal Zone Lymphoma (NMZL) is found primarily within the lymph nodes and does not involve other organs or the spleen at the start [11][1].

  • The Chronic Trigger: The triggers for NMZL are less clearly defined than the other subtypes, though it is still considered an indolent (slow-growing) condition [2].
  • Behavior: NMZL can sometimes be slightly more active than the other two types and may require systemic treatment (therapy that travels through the whole body) rather than localized care [11].

The Role of Chronic Stimulation

A unique feature of MZL is its connection to chronic immune stimulation. Essentially, your immune system is “stuck” in the “on” position because of a persistent invader or an autoimmune mistake, eventually causing B-cells to become cancerous [7][12].

Subtype Common Triggers & Associations
Gastric MALT Helicobacter pylori (H. pylori) [8]
Ocular MALT Chlamydia pneumoniae [13]
Salivary MALT Sjögren’s Syndrome (autoimmune) [14]
Thyroid MALT Hashimoto’s Thyroiditis (autoimmune) [15]
Splenic MZL Hepatitis C Virus (HCV) [16]

Why Your Subtype Matters

Your subtype tells your doctor how the disease is likely to behave. For a patient with gastric MALT, the “treatment” might simply be a course of antibiotics to kill the H. pylori infection, which can cure the lymphoma in many cases [3][17]. For someone with Splenic MZL, the doctor might focus on the spleen or treat an underlying Hepatitis C infection [18]. Understanding the specific anatomy and triggers of your diagnosis ensures you receive the most targeted, least invasive care possible.

Common questions in this guide

What are the three subtypes of marginal zone lymphoma (MZL)?
The three subtypes are Extranodal MALT lymphoma, Splenic MZL, and Nodal MZL. They are categorized based on where the lymphoma cells first develop in the body, such as outside the lymph nodes, in the spleen, or directly within the lymph nodes.
How does a chronic infection cause MALT lymphoma?
MALT lymphoma is often triggered when the immune system overreacts to a long-term infection or an autoimmune condition. For example, an ongoing H. pylori bacterial infection in the stomach can keep the immune system constantly activated, eventually causing B-cells to become cancerous.
Can marginal zone lymphoma be cured with antibiotics?
In some specific cases, yes. If you are diagnosed with gastric MALT lymphoma that was triggered by an H. pylori infection, taking a course of antibiotics to clear the bacteria can often cause the lymphoma to go away.
What is the treatment for Splenic MZL?
Treatment for Splenic MZL depends on your individual symptoms and whether you have an underlying infection. Many patients have no symptoms and can be monitored with a watch-and-wait approach for years, while others may need treatments directed at the spleen or therapies to treat an associated Hepatitis C infection.
Is Nodal MZL fast or slow-growing?
Nodal MZL is considered an indolent, or slow-growing, lymphoma. While it is slow-growing, it can sometimes be slightly more active than the other MZL subtypes and may require systemic treatments that travel through the whole body rather than localized care.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my biopsy and scans, which of the three subtypes (MALT, Nodal, or Splenic) do I have?
  2. 2.Have I been tested for specific triggers like H. pylori, Hepatitis C, or Chlamydia?
  3. 3.Given my subtype and trigger tests, can we start with a targeted approach like antibiotics or treating an underlying infection?
  4. 4.Does my subtype typically require immediate treatment, or is a 'watch and wait' approach appropriate for me?
  5. 5.How does the location of my lymphoma (e.g., in the stomach vs. lymph nodes) change the way you will monitor my progress?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Effective management strategies for patients with marginal zone lymphoma.

    Rosand CB, Valla K, Flowers CR, Koff JL

    Future oncology (London, England) 2018; (14(12)):1213-1222 doi:10.2217/fon-2017-0480.

    PMID: 29260925
  2. 2

    Marginal Zone Lymphoma: 2026 Update on Diagnosis and Management.

    Noor WD, Seymour JF, Cheah CY

    American journal of hematology 2026; (101(6)):1320-1340 doi:10.1002/ajh.70289.

    PMID: 41867085
  3. 3

    Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.

    Salar A, Domingo-Domenech E, Panizo C, et al.

    Blood 2017; (130(15)):1772-1774 doi:10.1182/blood-2017-07-795302.

    PMID: 28801448
  4. 4

    Splenic marginal zone lymphoma in Sweden 2000-2020: Increasing rituximab use and better survival in the elderly.

    Junlén HR, Sonnevi K, Lindén O, et al.

    EJHaem 2023; (4(3)):647-655 doi:10.1002/jha2.696.

    PMID: 37601869
  5. 5

    Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin.

    Vela V, Juskevicius D, Dirnhofer S, et al.

    Virchows Archiv : an international journal of pathology 2022; (480(2)):403-413 doi:10.1007/s00428-021-03186-3.

    PMID: 34494161
  6. 6

    [Chinese expert consensus on the diagnosis and management of ocular adnexal extranodal marginal zone mucosa-associated lymphoid tissue lymphoma (2023 edition)].

    , , , et al.

    Zhonghua zhong liu za zhi [Chinese journal of oncology] 2024; (46(4)):296-303 doi:10.3760/cma.j.cn112152-20230727-00042.

    PMID: 38303512
  7. 7

    Epidemiology of Marginal Zone Lymphoma.

    Cerhan JR, Habermann TM

    Annals of lymphoma 2021; (5()) doi:10.21037/aol-20-28.

    PMID: 33829216
  8. 8

    [Characteristics of Gastric Mucosa-associated Lymphoid Tissue Lymphoma in Korea].

    Kim TW, Kim JS

    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 2024; (84(6)):243-250 doi:10.4166/kjg.2024.108.

    PMID: 39716946
  9. 9

    Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance.

    Kalpadakis C, Pangalis GA, Sachanas S, et al.

    Blood 2018; (132(6)):666-670 doi:10.1182/blood-2018-02-833608.

    PMID: 29914978
  10. 10

    The many faces of nodal and splenic marginal zone lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop.

    Zamò A, van den Brand M, Climent F, et al.

    Virchows Archiv : an international journal of pathology 2023; (483(3)):317-331 doi:10.1007/s00428-023-03633-3.

    PMID: 37656249
  11. 11

    Nodal marginal zone lymphoma: Clinical features, diagnosis, management and treatment.

    Tadmor T, Polliack A

    Best practice & research. Clinical haematology 2017; (30(1-2)):92-98 doi:10.1016/j.beha.2016.08.026.

    PMID: 28288722
  12. 12

    Pleural Mucosa-associated Lymphoid Tissue Lymphoma with Trisomy 18.

    Okamoto N, Hayashi E, Tsukino M

    Internal medicine (Tokyo, Japan) 2019; (58(6)):891-892 doi:10.2169/internalmedicine.1780-18.

    PMID: 30449802
  13. 13

    Concurrent chronic follicular conjunctivitis and conjunctival MALT lymphoma potentially caused by Chlamydia pneumoniae.

    Chen YL, Jung SM, Hsiao CH

    IDCases 2025; (40()):e02251 doi:10.1016/j.idcr.2025.e02251.

    PMID: 40487821
  14. 14

    Cutaneous mucosa-associated lymphoid tissue lymphoma complicating Sjögren's syndrome: A case report and review of literature.

    Liu Y, Zhu J, Huang YH, et al.

    World journal of clinical cases 2022; (10(14)):4509-4518 doi:10.12998/wjcc.v10.i14.4509.

    PMID: 35663092
  15. 15

    Rare Primary Pulmonary Marginal Zone Lymphoma Presenting with Incidental Pulmonary Nodules.

    Ullah S, Ali M, Song M

    Case reports in pulmonology 2019; (2019()):7031868 doi:10.1155/2019/7031868.

    PMID: 31016061
  16. 16

    Higher incomplete remission rate of ocular extranodal marginal zone B-cell lymphoma in hepatitis B virus infectious patients.

    Chen YP, Yang IH, Tsai YJ, et al.

    Orbit (Amsterdam, Netherlands) 2026; (45(1)):79-86 doi:10.1080/01676830.2025.2553657.

    PMID: 41335486
  17. 17

    Clinical efficacy of the modified Helicobacter pylori eradication therapy for Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a meta analysis.

    Xie YL, He CY, Wei SQ, et al.

    Chinese medical journal 2020; (133(11)):1337-1346 doi:10.1097/CM9.0000000000000813.

    PMID: 32452892
  18. 18

    Splenic marginal zone lymphoma associated with hepatitis B virus infection, remission after viral treatment, and splenectomy: A case report and review of the literature.

    Ababou M, Mahtat EM, Jennane S, et al.

    Hematology/oncology and stem cell therapy 2021; (14(2)):153-155 doi:10.1016/j.hemonc.2019.05.007.

    PMID: 31306619

This page explains the subtypes of Marginal Zone Lymphoma for educational purposes only and does not replace professional medical advice. Always consult your oncologist or hematologist about your specific diagnosis and treatment plan.

Get notified when new evidence is published on Marginal zone lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.